{"id":133622,"date":"2022-08-31T08:12:03","date_gmt":"2022-08-31T12:12:03","guid":{"rendered":"https:\/\/44.250.171.167\/?p=133622"},"modified":"2022-10-06T04:43:54","modified_gmt":"2022-10-06T08:43:54","slug":"shilpa-medicare-ltd-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/shilpa-medicare-ltd-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Shilpa Medicare Ltd Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Shilpa Medicare Ltd Q1 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/4rB2G3iK3UE?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Shilpa Medicare Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/SHILPAMED\/\">SHILPAMED<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Vineet Gala of Monarch Networth asked about the timeline and the monetization of recombinant albumin. Vishnukant Bhutada MD answered that the company has received the Phase 1 clearance to carry out the study from govt. SHILPAMED should start the albumin trial by this year end and should be able to complete in nine months.<\/li>\n<\/ul>\n<ul>\n<li>Vineet Gala of Monarch Networth asked if the product is stabilized at a certain quantity. Vishnukant Bhutada MD said that around 200ltr to 1 kl the company has shifted the product and are able to scale the recombinant albumin.<\/li>\n<\/ul>\n<ul>\n<li>Rohan of ICICI asked about the sequential decline in the onco API and if there was some seasonality of revenues deferred to 2Q. Vishnukant Bhutada MD answered that onco API there is no such seasonality. SHILPAMED said that in the overall API industry lot of people have taken the material in stock. SHILPA\u2019s 1Q every year is normally seasonal.<\/li>\n<\/ul>\n<ul>\n<li>Rohan of ICICI enquired about the outlook on the CRAMS business and if there is any inventory in the books that\u2019s at the risk of write-off. Vishnukant Bhutada MD said there is no inventory the company is holding on in its books. SHILPAMED\u2019s CRAMS business is continuing but it is slowly coming down and SHILPAMED is managing inventory based on requirements.<\/li>\n<\/ul>\n<ul>\n<li>Rohan of ICICI asked about the delayed offtake for biologics revenue and a broad timeframe to utilize the cost invested in the plant. Alpesh Dalal CFO replied that some of company products have got delayed and it may take some time, in the increment, SHILPAMED is trying to look for more of CMO CDMO kind of opportunities to utilize facilities better.<\/li>\n<\/ul>\n<ul>\n<li>Rohan of ICICI asked that on the capex front, what\u2019s the capex the company is incurring in FY23. Vishnukant Bhutada MD replied that the only major one that is required is on the albumin side. Apart from that, for other investments, for the formulation and biologics no major capex is expected and for API, the company keeps expanding its capacity based on the need. On avg. SHILPAMED end up doing between INR40-50 crore investment in API.<\/li>\n<\/ul>\n<ul>\n<li>Rohan of ICICI asked the reason for GM pressure in 1Q23 and if it will be reversed in coming quarters. Vishnukant Bhutada MD replied that during 1Q23, the company had a double impact where some of the key products were under pricing pressure and also cost of some of company\u2019s other products increased. It might recover over a period of time but not immediately.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Shilpa Medicare Ltd (SHILPAMED) Q1 FY23 Earnings Concall Q&amp;A Highlights: Vineet Gala of Monarch Networth asked about the timeline and the monetization of recombinant albumin. Vishnukant Bhutada MD answered that the company has received the Phase 1 clearance to carry out the study from govt. SHILPAMED should start the albumin trial by [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Shilpa Medicare Ltd Q1 FY23 Earnings Conference Call Insights #SHILPAMED #Q1 #FY23 #Earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-133622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":176636,"url":"https:\/\/alphastreet.com\/india\/shilpa-medicare-ltd-shilpamed-q1-2026-earnings-call-transcript\/","url_meta":{"origin":133622,"position":0},"title":"Shilpa Medicare Ltd (SHILPAMED) Q1 2026 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Shilpa Medicare Ltd (NSE: SHILPAMED) Q1 2026 Earnings Call dated Aug. 13, 2025 Corporate Participants: Unidentified Speaker Monish Shah \u2014 Head of Investor Relations Keshav Bhutada \u2014 Executive Director Alpesh Dalal \u2014 Chief Financial Officer Analysts: Unidentified Participant Krisha Kansara \u2014 Analyst Suvaan Mittal \u2014 Analyst Sanjay Kumar \u2014 Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":129556,"url":"https:\/\/alphastreet.com\/india\/poonawalla-fincorp-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":133622,"position":1},"title":"Poonawalla Fincorp Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 16, 2022","format":false,"excerpt":"https:\/\/youtu.be\/F77en0wURhY Key highlights from Poonawalla Fincorp Ltd (POONAWALLA) Q4 FY22 Earnings Concall Management Update: POONAWALLA said its Housing arm delivered its highest ever profit before tax of INR101 crores against INR14 crores last year. Q&A Highlights: Nikhil Rungta from Nippon India asked about the 30 basis points impact due to\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":142267,"url":"https:\/\/alphastreet.com\/india\/shilpa-medicare-ltd-shilpamed-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":133622,"position":2},"title":"Shilpa Medicare Ltd (SHILPAMED) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"February 15, 2023","format":false,"excerpt":"Shilpa Medicare Ltd (NSE: SHILPAMED) Q3 FY23 Earnings Concall dated Feb. 15, 2023 Corporate Participants: Vishnukanth Bhutada\u00a0--\u00a0Managing Director Alpesh Dalal\u00a0--\u00a0Chief Financial Officer Analysts: Siddharth Rangnekar\u00a0--\u00a0CDR India -- Analyst Kaustav Bubna\u00a0--\u00a0BMSPL Capital -- Analyst Pankaj Pandekar\u00a0--\u00a0Individual Investor -- Analyst Badri Vishal\u00a0--\u00a0Bajaj -- Analyst Ritwik Sheth\u00a0--\u00a0One-Up Financial -- Analyst Tushar\u00a0--\u00a0MK Ventures --\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133436,"url":"https:\/\/alphastreet.com\/india\/borosil-renewables-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133622,"position":3},"title":"Borosil Renewables Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 24, 2022","format":false,"excerpt":"Key highlights from Borosil Renewables Ltd (BORORENEW) Q1 FY23 Earnings Concall Q&A Highlights: Rahul Dani of Monarch Networth asked that in opalware if there is a possibility for outsourced manufacturing. Pradeep Kheruka, Chairman replied that there is a possibility and the company is evaluating it and expects to bridge 2Q23\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":176641,"url":"https:\/\/alphastreet.com\/india\/shilpa-medicare-ltd-shilpamed-q2-2025-earnings-call-transcript\/","url_meta":{"origin":133622,"position":4},"title":"Shilpa Medicare Ltd (SHILPAMED) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Shilpa Medicare Ltd (NSE: SHILPAMED) Q2 2025 Earnings Call dated Nov. 14, 2024 Corporate Participants: Keshav Bhutada \u2014 Executive Director Alpesh Dalal \u2014 Chief Financial Officer Unidentified Speaker Analysts: Runjhun Jain \u2014 EY Sanjay Elangovan \u2014 Analyst Monish Shah Krisha Kansara Unidentified Participant Murali Nandan Presentation: Operator Ladies and gentlemen,\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":176638,"url":"https:\/\/alphastreet.com\/india\/shilpa-medicare-ltd-shilpamed-q4-2025-earnings-call-transcript\/","url_meta":{"origin":133622,"position":5},"title":"Shilpa Medicare Ltd (SHILPAMED) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Shilpa Medicare Ltd (NSE: SHILPAMED) Q4 2025 Earnings Call dated May. 26, 2025 Corporate Participants: Unidentified Speaker Monish Shah \u2014 Investor Relations Head Keshav Bhutada \u2014 Executive Director Alpesh Dalal \u2014 Chief Financial Officer Analysts: Unidentified Participant Presentation: operator Sat. SA Foreign. Ladies and gentlemen, you are connected to the\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=133622"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133622\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=133622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=133622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=133622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}